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Abstract
Background—This study investigated survival in people living with HIV being followed-up 
from five and ten years after antiretroviral therapy (ART) initiation in a multi-country Asian 
cohort.
Methods—We included patients in follow-up >5 years after ART initiation. Factors associated 
with mortality beyond five and ten years on ART were analysed using competing risk regression 
with time-updated variables.
Results—Of 13,495 patients retained after five years on ART, 279 subsequently died (0.56/100 
person-years). Increased mortality was associated with age >50 years (sub-hazard ratio [sHR] 
2.24, 95% confidence interval [95%CI] 1.58–3.15, compared to ≤40 years), HIV exposure through 
injecting drug use (sHR 2.17, 95%CI 1.32–3.56), HIV viral load ≥1000 copies/mL: sHR 1.52, 
95%CI 1.05–2.21, compared to <400), regimen (second-line regimen: sHR 2.11, 95%CI 1.52–
2.94, and third-line regimen: sHR 2.82, 95%CI 2.00–3.98, compared to first-line regimen), HBV 
co-infection (sHR 2.23, 95%CI 1.49–3.33), fasting plasma glucose ≥126 mg/dL (sHR 1.98, 
95%CI 1.22–3.21, compared to <100 mg/dL), and estimated glomerular filtration rate <60 
mL/min/1.73m2 (sHR 2.57, 95%CI 1.56–4.22). Decreased mortality was associated with 
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transmission through male-to-male sexual contact (sHR 0.44, 95%CI 0.22–0.88, compared to 
heterosexual transmission) and higher CD4 count (200–349 cells/μL: sHR 0.27, 95%CI 0.20–0.38, 
350–499 cells/μL: sHR 0.10, 95%CI 0.07–0.16, and ≥500 cells/μL: sHR 0.09, 95%CI 0.06–0.13, 
compared to <200 cells/μL). Results after ten years were similar, but most associations were 
weaker due to limited power.
Conclusions—Next to preventing ART failure, HIV programs should carefully monitor and 
treat comorbidities, including hepatitis, kidney disease and diabetes, to optimise survival after 
long-term ART exposure.
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Introduction
The expansion of combination antiretroviral therapy (ART) has substantially improved 
treatment outcomes of people living with HIV (PLHIV) [1]. For instance, life expectancy in 
PLHIV has improved dramatically over the years. According to a recent meta-analysis, 
PLHIV starting ART at 20 years of age are estimated to live an additional 37 years [2]. 
However, the additional years of life were estimated to be almost ten years less in those 
living in in low- and middle-income countries. Gains in survival outcomes are still to be 
made in regions with mixed country incomes, such as the Asia Pacific.
Historically, studies on survival have primarily focussed on survival after ART initiation [3–
7]. A previous study on the TREAT Asia HIV Observational Database - Low Intensity 
Transfer (TAHOD-LITE) showed a mortality rate of 1.6 per 100 person-years (pys) in Asian 
PLHIV [3]. Country- and region-specific studies have reported somewhat higher mortality 
rates. In India, one study found five-year mortality rates ranging from 6.8 to 7.2 per 100 pys 
[4], whereas another study found a mortality rate of 8.1 per 100 pys over a median follow-up 
of 1.3 years [5]. A study from China reported a mortality rate of 3.1 per 100 pys over a 
median follow-up of 4.3 years [6]. Few studies investigated survival based on longer follow-
up data, including a Chinese study reporting a mortality rate of 3.4 per 100 pys, during 
follow-up from ART initiation until ten years thereafter [7], and a Korean study describing a 
mortality rate of 4.6 per 100 pys, with a median survival of 16.7 years after HIV diagnosis 
[8].
Studies investigating survival have shown that predictors of survival are related to adherence 
to treatment and patient health at the start of ART, such as CD4 count, AIDS-defining 
illnesses, poor functional status, low body weight, and TB co-infection [4–6]. Another 
finding survival studies have in common is that the overwhelming majority of mortality 
occurs in the early stages after HIV diagnosis or ART initiation [3–5, 7, 8]. Therefore, 
predictors of mortality are likely to be skewed towards the part of the population that enters 
care in poor health and has difficulties with adherence. Those who have survived and 
remained in care beyond those early stages are reflective of a more stable group of PLHIV, 
who have overcome the first challenging few years after diagnosis and ART initiation.
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Current guidelines advocate the test-and-treat approach, in which people start ART 
immediately after HIV diagnosis [9], when – ideally – CD4 counts are still high and patients 
do not show signs of advanced HIV disease. With the implementation of these guidelines, 
mortality rates in the early stages of ART can be expected to decrease as well, leading to a 
growing population of PLHIV who have had multiple years of ART experience. Although 
the currently recommended ART regimens are more tolerable than those introduced in 
earlier years [10], newer and less toxic antiretroviral drugs are not widely available in low- 
and middle-income countries, including some countries in Asia. Many PLHIV in the region 
are still exposed to ART that have been associated with altered metabolic functioning [11, 
12], thereby predisposing them to non-communicable diseases such as diabetes, 
cardiovascular disease and kidney disease which can result in fatal outcomes [13–16]. Taken 
together, this calls for studies focussing their attention on survival after long-term ART use 
which incorporates factors related to longer duration of ART exposure.
The latest TAHOD-LITE transfer provides over a decade of clinical data of PLHIV and is 
one of the most sizable multi-country cohorts in the Asia-Pacific region to date. This 
provided us with the unique opportunity to investigate survival after long-term ART 
exposure in a large population of PLHIV. The aim of this study was to assess factors 
associated with mortality from five and from ten years after ART initiation.
Methods
Study design and patients
TAHOD-LITE is a sub-study of the TREAT Asia HIV Observational Database (TAHOD), a 
prospective observational cohort of the International Epidemiology Databases to Evaluate 
AIDS. Both studies have been detailed previously [3, 17–19]. The 2017 TAHOD-LITE data 
transfer collected data on all patients receiving care at ten clinical sites in eight Asian 
countries and territories. Collected data was limited to demographics, hepatitis serology, 
ART history, HIV-related laboratory results, and fasting plasma glucose (FPG) and 
creatinine levels. All data, including information on deaths and clinic transfers, was acquired 
from the medical records. Institutional Review Board approvals were obtained at all 
participating sites, the data management and analysis centre (The Kirby Institute, UNSW 
Sydney, Australia), and the coordinating centre (TREAT Asia/amfAR, Bangkok, Thailand). 
We included adults (aged ≥18 years at first clinic visit) who started triple ART between 
January 1992-June 2012, were alive and in active follow-up at five years after ART initiation 
and had at least one clinic visit thereafter.
Variables and definitions
Variables included in our study were sex, age group, HIV exposure category, year of ART 
initiation, HIV viral load, CD4 count, regimen, treatment interruptions, hepatitis B (HBV) 
co-infection (based on HBsAg test result), hepatitis C (HCV) co-infection (based on anti-
HCV test result), FPG, and estimated glomerular filtration rate (eGFR, as calculated 
according to the CKD-EPI equation [20]). We also included pre-ART CD4 count, defined as 
the most recent available CD4 count taken within six months prior to ART initiation. ART 
regimen was based on changes within the regimen, regardless of the reason for any changes 
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as these were not available in TAHOD-LITE. First-line ART regimen was defined as the first 
combination regimen with three or more antiretroviral drugs. Second-line ART regimen was 
defined as subsequent to the first regimen, undertaken for at least fourteen days, which either 
had one antiretroviral drug class change or two or more antiretroviral drug changes within a 
class, and third-line ART regimen was similarly defined as subsequent to the second 
regimen. In line with other literature [21, 22], each break from ART (i.e. not taking any 
antiretroviral drugs) of at least 14 days was considered a treatment interruption.
Statistical analysis
Patient characteristics at ART initiation were provided for all patients who had retained in 
care beyond five years post-ART initiation and compared to patients who had started ART 
between January 1992-June 2012, but had been excluded because they had died, transferred 
out, or become lost to follow-up (LTFU) within five years after ART initiation (i.e. patients 
who theoretically could have been on ART for more than five years). Furthermore, for those 
retained in care beyond five years post-ART initiation we provided the clinical profile at five 
years on ART taken as the latest available clinical data prior to or at that time point.
Since the focus of our study was on survival after long-term exposure to ART, follow-up 
time started from five years after ART initiation and ended on the date of death or censor 
date. Patients who remained in active follow-up, had transferred to another clinic or became 
LTFU (defined not seen at clinic in last 12 months) were censored on the date of last visit. 
Mortality rates were calculated per 100 pys of follow-up and the cumulative incidence of 
mortality and LTFU were plotted using the competing risk framework in which each 
outcome was a competing risk for the other outcome [23].
Fine and Gray competing risk regression [24] was used to calculate sub-Hazard Ratios 
(sHR) with 95% confidence intervals (95%CI) for factors associated with mortality from 
five years after ART initiation, with LTFU treated as a competing risk. All variables were 
time updated. Regimen and treatment interruptions were counted starting at ART initiation. 
If for any variable, data was unavailable throughout follow-up, it was categorised as missing. 
A multivariable model was built using a stepwise backwards selection procedure in which 
variables were considered that were univariable associated with mortality at Wald’s test p 
<0.10. In an additional analysis conducted similar to the main analysis, we investigated 
survival from ten years after ART initiation. We thus excluded all patients who were not 
retained in care beyond ten years after ART initiation and follow-up time started from ten 
years post-ART initiation.
Data management and statistical analyses were performed using SAS software version 9.4 
(SAS Institute Inc., Cary, NC, USA) and Stata software version 14.2 (StataCorp, College 
Station, TX, USA).
Result
Figure 1 shows a flow chart of the patient selection process. Among the 40921 patients who 
were included in TAHOD-LITE, 23,461 had started ART at least five years prior to the 
transfer date. Of these, we excluded 9966 patients who did not attain five years of follow-up 
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because they had died (9%), transferred out (29%) became LTFU (55%), or did not have a 
clinic visit after five years on ART but were not yet considered LTFU at five years post-ART 
initiation under the 12-month LTFU definition (7%). The final population eligible for our 
analysis comprised 13,495 patients who were in active follow-up five years from ART 
initiation.
Table 1 compares characteristics at ART initiation of eligible patients who retained in care 
beyond five years on ART versus excluded patients who started ART at least five years prior 
to the transfer date but did not retain in care beyond five years on ART. Of the 13,495 
eligible patients, 9463 (70%) were male and 8087 (60%) had heterosexual HIV exposure 
category. Median ART initiation year was 2007 (IQR 2005–2010) and median CD4 count at 
ART initiation was 147 cells/μL (IQR 55–243) among the 8964 (66%) patients who had 
available data on pre-ART CD4 count. Positive HBsAg and anti-HCV were seen in 733 
(5%) and 820 (6%) of patients, respectively, whereas 5523 (41%) and 7304 (54%), 
respectively, had never been tested on these serological markers. Excluded patients were 
largely similar to the eligible patients in terms of sex and age, but a smaller proportion was 
tested on HBV and HCV coinfection. Furthermore, a lower proportion of the excluded 
patients had MSM HIV exposure category compared to the included patiens. Median ART 
initiation year was more recent in the excluded patients (2009, IQR 2006–2011). Median 
pre-ART CD4 count was comparable between eligible and excluded patients, however, in the 
excluded patient who died before five years on ART, 70% had a pre-ART CD4 count of 
<200 copies/uL compared to 60% in those who died after five years of ART exposure.
Table 2 displays the clinical characteristics at five years on ART of the included. At five 
years on ART, median CD4 count was 457 cells/μL (IQR 310–627), median HIV viral load 
was 47 copies/mL (IQR 19–399), median age was 40 years (IQR 35–47) and 839 (62%) 
patients were still on their first regimen. Treatment interruptions were observed in 2336 
(17%) of patients by five years on ART. A large proportion of patients had unknown FPG 
(54%) or eGFR (48%) up to five years after ART initiation, but in those who had this data 
available median FPG was 89 mg/dL (IQR 80–99) and median eGFR was 99 mL/min/
1.73m2 (IQR 85–110). Furthermore, the majority of included patients were from India 
(55%), followed by Cambodia (13%), Vietnam (10%), Singapore (9%), Hong Kong (4%), 
Indonesia (3%), South Korea (3%), and Taiwan (3%).
Survival after five years on ART
Among the 13,495 patients who were retained in care from five years after ART initiation, 
279 (2%) subsequently died (incidence rate [IR] 0.56 per 100 pys), 628 (5%) transferred out 
(IR 1.27 per 100 pys), and 2403 (18%) became LTFU (IR 4.85 per 100 pys) over 49,533 
person-years. Median follow-up time from five years after ART initiation was 3.1 years 
(IQR 1.4–5.5), translating into a total ART exposure time of 8.1 years (IQR 5.4–10.5) Figure 
2 shows the cumulative incidence of mortality and LTFU from five years after ART 
initiation. Mortality rates were higher for men, older age, higher HIV viral load, lower CD4 
count (pre-ART and beyond five years on ART), second- and third-line regimens, more 
treatment interruptions, HBV co-infection, HCV co-infection, higher FPG levels, and 
decreased eGFR. In multivariable analysis (Table 3), age >50 years (sHR 2.24, 95%CI 1.58–
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3.15, compared to ≤40 years), HIV exposure through injecting drug use (sHR 2.17, 95%CI 
1.32–3.56), higher HIV viral load ≥1000 copies/mL: sHR 1.52, 95%CI 1.05–2.21, compared 
to <400), regimen (second-line regimen: sHR 2.11, 95%CI 1.52–2.94, and third-line 
regimen: sHR 2.82, 95%CI 2.00–3.98, compared to first-line regimen), HBV co-infection 
(sHR 2.23, 95%CI 1.49–3.33), FPG ≥126 mg/dL (sHR 1.98, 95%CI 1.22–3.21, compared to 
<100 mg/dL), and eGFR <60 mL/min/1.73m2 (sHR 2.57, 95%CI 1.56–4.22) were 
associated with increased mortality after five years on ART, whereas HIV exposure through 
male to male sex (sHR 0.44, 95%CI 0.22–0.88) and higher CD4 count (200–349 cells/μL: 
sHR 0.27, 95%CI 0.20–0.38, 350–499 cells/μL: sHR 0.10, 95%CI 0.07–0.16, and ≥500 
cells/μL: sHR 0.09, 95%CI 0.06–0.13, compared to <200 cells/μL) were associated with 
decreased mortality. Borderline associations with increased mortality were found for HIV 
viral load 400–999 copies/mL (sHR 2.02, 95%CI 0.99–4.10, compared to <400) and ≥3 
treatment interruptions (sHR 1.52 95%CI 0.97–2.38, compared to no interruptions). No 
associations were found between mortality and sex, pre-ART CD4 count, period of ART 
initiation, or HCV co-infection.
Survival after ten years on ART
A total of 3996 patients were still in care ten years after ART initiation. Of these, 64 (2%) 
subsequently died (IR 0.72 per 100 pys), 115 (3%) transferred out (IR 1.29 per 100 pys), and 
434 (11%) became LTFU (IR 4.86 per 100 pys) over 8921 person-years. In univariable 
analysis, HIV exposure category, HIV viral load, CD4 count (pre-ART and beyond five 
years on ART), regimen, treatment interruptions, HBV co-infection, and HCV co-infection 
were associated with increased mortality from ten years after ART initiation. In 
multivariable analysis, only HIV exposure through injecting drug use (sHR 6.33 95%CI 
2.21–18.14, compared to heterosexual), CD4 count beyond ten years on ART (200–349 
cells/uL: sHR 0.30, 95%CI 0.16–0.57; 350–499 cells/uL: sHR 0.05, 95%CI 0.04–0.15, and 
≥500 cells/uL: sHR 0.08, 95%CI 0.04–0.15, compared to <200 cells/uL), and regimen 
(second-line regimen: sHR 2.81, 95%CI 1.14–7.05, and third-line regimen: sHR 3.59, 
95%CI 1.47–8.77, compared to first regimen) were associated with increased mortality 
(Supplementary Table). Other factors largely showed similar trends to main analysis, but 
with weaker associations.
Discussion
The mortality rate in the 13,495 PLHIV who were retained in care beyond five years after 
ART initiation was 0.56 per 100 pys. About 30% of these patients were still alive and in 
active follow-up beyond ten years after they started ART and had a mortality rate of 0.72 per 
100 pys. Factors associated with increased mortality rates beyond five years after ART 
initiation were older age, HIV exposure through injecting drug use, later regimen, more 
treatment interruptions, and HBV co-infection, as were higher viral load, high FPG, and 
decreased eGFR measured beyond five years on ART. HIV exposure through male to male 
sex and higher CD4 cell count measured beyond five years on ART were associated with 
decreased mortality rates. Results related to mortality after ten years on ART were roughly 
similar, although the evidence for most associations were weaker due to limited power.
Bijker et al. Page 6













The current study showed a mortality rate of 0.56 per 100 pys from five years after ART 
initiation. When the study population was restricted to those who retained in care an 
additional five years, the mortality rate increased slightly, to 0.72 per 100 pys from ten years 
after ART initiation, most likely due to further aging of the population. In comparison, the 
Antiretroviral Therapy Cohort Collaboration (ART-CC) conducted in high-income Western 
settings found a somewhat higher mortality rate of 1.29 per 100 pys in PLHIV who had 
retained in care beyond ten years on ART [25]. While in a previous TAHOD-LITE study 
male sex, lower pre-ART CD4 count and ART initiation in earlier calendar year were 
indicated as important predictors of survival in the first years on ART [3], these factors were 
not confirmed as important for survival after long-term exposure to ART. Similarly, the 
ART-CC study did not substantiate a relation between in mortality beyond ten years on ART 
and sex or pre-ART CD4 count [25].
CD4 count at the start of ART can be considered one of the most critical predictors of 
survival in the first years after ART initiation [26]. In line with this, a pre-ART CD4 count of 
<200 cells/uL was observed in a substantially higher proportion of TAHOD-LITE patients 
who died within five years after ART initiation (70%) compared to those who died beyond 
five years on ART (60%) and those who remained alive (46%). In many South-East Asian 
countries, PLHIV still commonly present to care with low CD4 counts. These patients have 
considerably lower chance of survival beyond the next few years then those who start ART 
in better health [3, 7, 8, 27]. which further underlines the importance of ART treatment 
guidelines which recommended immediate start of ART, with priority being given to those 
with lower CD4 counts [9]. Evidence shows that as time passes by and patients remain in 
care, the association between pre-ART CD4 count and survival dissipates when accounted 
for CD4 counts at later time points [28]. Consistent with this evidence, our study showed 
that pre-ART CD4 count was not associated with mortality after long-term ART exposure, 
when controlling for CD4 count from five years on ART onwards and other confounders.
Corroborating findings from other studies [21, 25, 29], high viral load and low CD4 count 
from five years after ART initiation onwards contributed to poorer survival. Furthermore, 
mortality rates were higher among those with treatment interruptions, although this 
association became weaker in multivariable analysis. Our findings thus confirm the 
importance of continuity in HIV treatment and management. In case of virological, 
immunological, or clinical failure, it is warranted to check patients’ adherence and offer 
adherence support where appropriate [10]. Ongoing treatment failure despite optimal 
adherence commonly necessitates a switch in regimen to improve HIV outcomes [10, 30, 
31]. According to a previous TAHOD study, about half of those with treatment failure did 
not switch regimens in the 12 months after which a regimen was determined as failing in 
terms of clinical progression, virological failure or immunological failure [32]. As delaying 
progression from a first-line regimen to a second-line regimen has been associated with 
poorer survival [33], the delay in switching regimens potentially explains the higher 
mortality we observed in those who were on a second- or third-line regimen in our cohort.
We found a two-fold increased mortality hazard for viral loads between 400–999 copies/mL, 
compared to virological suppression at <400 copies/mL. The evidence we found for this 
associations was weak, possibly because it was based on a small number of observations (9 
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deaths over 606 pys) and we did not differentiate between multiple assessments of low level 
viremia within a patient or one-off assessments of HIV viral load 400–999 copies/mL. 
Previous studies have shown inconsistent results regarding associations of persistent low-
level viremia with all-cause mortality and AIDS events [34–36]. However, one cohort study 
demonstrated increased levels of markers related to cardiovascular disease, among those 
with low-level viremia [36]. Collectively, these findings hint towards a potential pathway 
from low-level viremia to cardiovascular disease and mortality, which may only become 
apparent after many years on ART. Further studies are needed to investigate the importance 
of low-level viremia and clinical outcomes, especially in the stable population of PLHIV 
who have been exposed to long-term ART.
Cardiovascular disease and other chronic non-communicable diseases such as diabetes, 
kidney disease, and cancer are highly prevalent in PLHIV compared to the general 
population [37–39]. Several studies with a median follow up of less than five years after 
ART initiation have reported increased mortality among PLHIV with poor kidney function 
[15, 40, 41] and high glucose levels or diabetes [13, 14]. Our study showed that beyond five 
years after ART initiation, there was about a two-fold increased mortality hazard in those 
with eGFR <60 mL/min/1.73m2 and a more than two-fold increased hazard for those with 
FPG ≥126 mg/dL. A rise in prevalence of kidney disease and diabetes has been observed in 
those with longer exposure to ART [11, 42] and prolonged presence of these conditions 
might be increasingly important for survival in the long run. Taken together with evidence 
that AIDS-related mortality has been decreasing in PLHIV in the Asia Pacific [43], this 
underlines the importance of allocating resources to monitoring glucose levels, kidney 
function, and presumably other markers of non-communicable comorbidities, and intervene 
where appropriate to further advance survival in PLHIV.
In our study, being HBV co-infected was associated with increased mortality. Similar 
findings have been reported for study populations in Thailand and South Korea [44, 45]. 
There have also been reports of associations between mortality and both HCV and HBV co-
infection in Cambodia [46] or mortality and HCV, but not HBV co-infection in China [7, 
47]. Most likely the association we found had to do with availability of treatment for HBV, 
such as the antiretroviral drug tenofovir which is used as treatment for HIV as well as HBV. 
This is exemplified by a Taiwanese study that confirmed increased mortality among PLHIV 
with HBV before the introduction of tenofovir in 2011, but did not find a difference in 
mortality among those with or without HBV after 2011 [48].
Our findings indicated differences in survival by HIV exposure category. Compared to those 
with heterosexual HIV exposure, survival was better in men who have sex with men, 
whereas it was worse in people who injected drugs. Previous literature has shown that men 
who have sex with men are more likely to have optimal levels of adherence [49]. Suboptimal 
adherence is closely related to treatment failure and this may explain why men who have sex 
with men have superior survival outcomes as well. Increased mortality in injecting drug use 
was also observed in the ART-CC cohort [25]. Findings from this cohort further showed that 
non-AIDS related mortality is over three times more likely in people who inject drugs 
compared to those who do not inject drugs. The high mortality rate in people who inject 
drugs in our study population might also be explained by non-AIDS causes of death such as 
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drug overdosing, cardiovascular disease, liver disease, and accidents, which are commonly 
seen in people using illicit drugs [50].
This study had several limitations. As with all observational studies, we cannot rule out the 
possibility of unmeasured confounding. The TAHOD-LITE cohort includes all adult patients 
enrolled in care from selected clinical sites that participate in TAHOD, and data of over 
50,000 patients is transferred from – in some clinics paper-based – medical files. Due to the 
tremendous size of the cohort it is outside the scope of TAHOD-LITE to collect detailed 
data on patients’ laboratory results beyond CD4 count, HIV viral load, FPG, and serum 
creatinine. As a result, we could not assess the effect of other markers for comorbid non-
communicable conditions, such as cardiovascular disease, liver disease, and certain cancers. 
Our findings may be biased to some extent due to missing data and infrequently performed 
laboratory testing of variables that were collected in this study. For example, HBV 
coinfection was based on presence of one positive test results and it is possible that we 
misclassified patients if the virus had cleared prior to testing or infection occurred after 
testing. It should be noted that active tracing of patients LTFU or linkage to death registries 
was not part of the TAHOD-LITE study protocol and an uncertain proportion of patients 
considered LTFU may have died or self-transferred to other clinics [51, 52]). In addition, 
data on cause of death were not routinely collected, so we were unable to distinguish 
between deaths related to HIV and other medical causes, which could have been a valuable 
addition to our analysis considering our findings regarding kidney function and glucose 
levels. Furthermore, our findings are not necessarily representative of all Asian PLHIV with 
long-term ART exposure, partly due to differences between the included patients and those 
we had to exclude due to insufficient follow-up time or attrition prior to five years on ART.
In summary, our findings suggest low mortality rates among PLHIV in Asia-Pacific who 
were retained in care beyond five years after ART initiation compared to reported short-term 
rates. Our study confirmed that maintaining high CD4 count, undetectable HIV viral load 
and not interrupting treatment benefit survival outcomes. Additionally, we found improved 
survival in those with favourable levels of FPG and eGFR. Thus, to optimise long-term 
survival outcomes in PLHIV, it is crucial to carefully monitor and manage comorbidities, 
such as hepatitis, diabetes, and kidney disease, next to preventing treatment failure.
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Table 1
Characteristics at ART initiation, of patients who were and were not eligible for analysis of survival from five 
years after ART initiation
patients included in the analysis of survival from five 
years after ART initiation
patients who started ART more than five years ago 
but were excluded from the analysis
Total, n (%) Died, n (%) LTFU, n (%) Total, n (%) Died, n (%) LTFU, n (%)
a
Total 13495 (100) 279 (100) 2403 (100) 9966 (100) 915 (100) 5455 (100)
Sex       
 Female 4032 (29.9) 54 (19.4) 625 (26.0) 2923 (29.3) 175 (19.1) 1678 (30.8)
 Male 9463 (70.1) 225 (80.6) 1778 (74.0) 7043 (70.7) 740 (80.9) 3777 (69.2)
Age group (years)       
 ≤40 9947 (73.7) 175 (62.7) 1857 (77.3) 7307 (73.3) 576 (63) 3987 (73.1)
 41-50 2428 (18.0) 51 (18.3) 394 (16.4) 1808 (18.1) 164 (17.9) 1023 (18.8)
 ≥51 1120 (8.3) 53 (19.0) 152 (6.3) 851 (8.5) 175 (19.1) 445 (8.2)
HIV exposure category       
 Heterosexual 8087 (59.9) 217 (77.8) 1284 (53.4) 6185 (62.1) 706 (77.2) 2650 (48.6)
 MSM 1235 (9.2) 13 (4.7) 54 (2.2) 376 (3.8) 57 (6.2) 109 (2.0)
 IDU 563 (4.2) 24 (8.6) 43 (1.8) 330 (3.3) 78 (8.5) 70 (1.3)
 Other 3610 (26.8) 25 (9.0) 1022 (42.5) 3075 (30.9) 74 (8.1) 2626 (48.1)
Period of ART 
initiation
      
 ≤2002 1271 (9.4) 55 (19.7) 370 (15.4) 366 (3.7) 59 (6.4) 205 (3.8)
 2003-2005 2678 (19.8) 95 (34.1) 813 (33.8) 1503 (15.1) 195 (21.3) 338 (6.2)
 2006-2009 5952 (44.1) 109 (39.1) 1153 (48.0) 4163 (41.8) 378 (41.3) 2310 (42.3)
 ≥2010 3594 (26.6) 20 (7.2) 67 (2.8) 3934 (39.5) 283 (30.9) 2602 (47.7)
pre-ART CD4 cell 
count (cells/μL)
      
 <200 5687 (42.1) 166 (59.5) 750 (31.2) 4587 (46.0) 642 (70.2) 1868 (34.2)
 200-349 2512 (18.6) 23 (8.2) 265 (11.0) 1590 (16.0) 79 (8.6) 909 (16.7)
 ≥350 765 (5.7) 9 (3.2) 113 (4.7) 523 (5.2) 31 (3.4) 292 (5.4)
 Missing 4531 (33.6) 81 (29.0) 1275 (53.1) 3266 (32.8) 163 (17.8) 2386 (43.7)
Positive HBsAg test 
b       
 No 7239 (53.6) 131 (47.0) 812 (33.8) 3625 (36.4) 456 (49.8) 2054 (37.7)
 Yes 733 (5.4) 31 (11.1) 51 (2.1) 362 (3.6) 64 (7.0) 152 (2.8)
 Missing/not tested 5523 (40.9) 117 (41.9) 1540 (64.1) 5979 (60.0) 395 (43.2) 3249 (59.6)
Positive Anti-HCV test 
b
      
 No 5371 (39.8) 117 (41.9) 313 (13.0) 1991 (20.0) 371 (40.5) 823 (15.1)
 Yes 820 (6.1) 23 (8.2) 26 (1.1) 380 (3.8) 96 (10.5) 73 (1.3)
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patients included in the analysis of survival from five 
years after ART initiation
patients who started ART more than five years ago 
but were excluded from the analysis
Total, n (%) Died, n (%) LTFU, n (%) Total, n (%) Died, n (%) LTFU, n (%)
a
 Missing/not tested 7304 (54.1) 139 (49.8) 2064 (85.9) 7595 (76.2) 448 (49.0) 4559 (83.6)
LTFU, lost to follow-up; MSM, men who have sex with men; IDU, injecting drug use; ART, antiretroviral therapy
a
Only included patients considered LTFU at five years post-ART initiation under the 12-month definition for LTFU
b
Ever tested positive on HBsAg or anti-HCV.
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Table 2
Clinical profile at five years on ART, of patients included in the main analysis
Total, n (%) Died, n (%)
CD4 cell count (cells/μL)   
 <200 1561 (11.6) 99 (35.5)
 200-349 2500 (18.5) 64 (22.9)
 350-499 2884 (21.4) 36 (12.9)
 ≥500 4793 (35.5) 43 (15.4)
 Missing 1757 (13.0) 37 (13.3)
Viral load (copies/mL)   
 <50 5264 (39) 84 (30.1)
 50-399 159 (1.2) 2 (0.7)
 ≥400 887 (6.6) 57 (20.4)
 Missing 7185 (53.2) 136 (48.7)
Current regimen 
a   
 First 8393 (62.2) 131 (47.0)
 Second 3865 (28.6) 105 (37.6)
 Third 1237 (9.2) 43 (15.4)
Treatment interruptions 
a   
 None 11159 (82.7) 177 (63.4)
 1-2 2149 (15.9) 82 (29.4)
 ≥3 187 (1.4) 20 (7.2)
Fasting plasma glucose (mg/dL)   
 <100 4884 (36.2) 58 (20.8)
 100-125 946 (7.0) 18 (6.5)
 ≥126 385 (2.9) 13 (4.7)
 Not tested/missing 7280 (53.9) 190 (68.1)
eGFR (mL/min/1.73m2)   
 ≥60 6815 (50.5) 91 (32.6)
 <60 269 (2.0) 18 (6.5)
 Not tested/missing 6411 (47.5) 170 (60.9)
FPG, fasting plasma glucose; eGFR, estimated glomerular filtration rate.
a
Counted from ART initiation.
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Table 3
Factors associated with survival beyond five years on ART
Univariable analysis 
a Multivariable analysis
Person-years Deaths Mortality rate 
(/100pys)
sHR 95%CI p-value sHR 95%CI p-value
Sex          
 Female 13763.1 54 0.39 1.00   1.00   
 Male 35770.3 225 0.63 1.43 1.05-1.95 0.023 0.98 0.72-1.34 0.911
Age group (years)      <0.001   <0.001
 ≤40 21058.6 90 0.43 1.00   1.00   
 41-50 19014.3 98 0.52 1.39 1.04-1.86 0.025 1.33 0.99-1.79 0.061
 <50 9460.5 91 0.96 2.50 1.85-3.37 <0.001 2.24 1.58-3.15 <0.001
HIV exposure category      <0.001   <0.001
 Heterosexual 29705.9 217 0.73 1.00   1.00   
 MSM 4307.5 13 0.30 0.23 0.11-0.45 <0.001 0.44 0.22-0.88 0.020
 IDU 1735.8 24 1.38 2.07 1.33-3.23 0.001 2.17 1.32-3.56 0.002
 Other 13784.2 25 0.18 0.59 0.33-1.05 0.077 0.60 0.33-1.12 0.112
Viral load (copies/mL)      <0.001   0.030
 <399 23544.2 108 0.46 1.00   1.00   
 400-999 605.5 9 1.49 3.50 1.73-7.06 <0.001 2.02 0.99-4.10 0.052
 ≥1000 3542.4 66 1.86 3.54 2.52-4.96 <0.001 1.52 1.05-2.21 0.027
 Not tested 21841.3 96 0.44  1.22 0.86-1.71 0.264 0.81 0.54-1.21 0.306
CD4 count (cells/μL)      <0.001   <0.001
 <200 5164.8 153 2.96 1.00   1.00   
 200-349 8075.7 55 0.68 0.25 0.18-0.35 <0.001 0.27 0.20-0.38 <0.001
 350-499 10444.1 23 0.22 0.09 0.05-0.14 <0.001 0.10 0.07-0.16 <0.001
 ≥500 20461.5 34 0.17 0.07 0.05-0.1 <0.001 0.09 0.06-0.13 <0.001
 Not tested 5387.4 14 0.26 0.13 0.08-0.21 <0.001 0.22 0.12-0.39 <0.001
pre-ART CD4 count (cells/
μL)
     <0.001   0.265
 <200 20921.1 166 0.79 1.00      
 200-349 7693.5 23 0.30 0.40 0.26-0.62 <0.001 0.76 0.48-1.20 0.236
 350-499 2039.4 9 0.44 0.56 0.29-1.11 0.096 1.38 0.69-2.78 0.363
 Not tested 18879.4 81 0.43 0.81 0.60-1.09 0.164 0.97 0.70-1.34 0.846
Year of ART initiation      0.099   0.193
 ≤2002 10094.6 55 0.54 1.00   1.00   
 2003-2005 15175.8 95 0.63 1.11 0.8-1.54 0.544 0.90 0.64-1.28 0.569
 2006-2009 20647.7 109 0.53 0.79 0.56-1.11 0.180 0.71 0.49-1.01 0.058
 ≥2010 3615.3 20 0.55 0.67 0.36-1.24 0.199 0.67 0.35-1.28 0.225
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Univariable analysis 
a Multivariable analysis
Person-years Deaths Mortality rate 
(/100pys)
sHR 95%CI p-value sHR 95%CI p-value
Current regimen 
b      <0.001   <0.001
 First-line 22870.5 59 0.26 1.00   1.00   
 Second-line 17002.0 112 0.66 2.73 1.98-3.75 <0.001 2.11 1.52-2.94 <0.001
 Third-line 9660.9 108 1.12 4.60 3.31-6.41 <0.001 2.82 2.00-3.98 <0.001
Treatment interruptions 
b      <0.001   0.177
 None 38815.5 163 0.42 1.00   1.00   
 1-2 9455.0 87 0.92 2.09 1.58-2.78 <0.001 1.07 0.80-1.44 0.633
 ≥3 1262.9 29 2.30 4.89 3.2-7.46 <0.001 1.52 0.97-2.38 0.065
HBV co-infection 
c         <0.001
 No 25427.0 131 0.52 1.00   1.00   
 Yes 2641.8 31 1.17 2.30 1.54-3.42 <0.001 2.23 1.49-3.33 <0.001
 Not tested 21464.7 117 0.55 1.01 0.74-1.38 0.962  1.01 0.74-1.37 0.954
HCV co-infection 
c          
 No 18935.4 117 0.62 1.00   1.00   
 Yes 2665.0 23 0.86 1.45 0.87-2.42 0.149 0.96 0.53-1.73 0.881
 Not tested 27933.0 139 0.50 0.85 0.58-1.24 0.389 0.84 0.52-1.35 0.471
FPG (mg/dL)      <0.001   0.022
 <100 18809.5 77 0.41 1.00   1.00   
 100-125 4273.1 24 0.56 1.24 0.77-1.98 0.375 1.18 0.74-1.87 0.490
 ≥126 1825.5 26 1.42 2.80 1.77-4.41 <0.001 1.98 1.22-3.21 0.006
 Not tested 24625.3 152 0.62 1.06  0.72-1.57  0.754 0.81 0.52-1.26 0.357
eGFR (mL/min/1.73m2)          
 ≥60 25778.6 97 0.38 1.00   1.00   
 <60 1290.6 26 2.01 5.23 3.3-8.3 <0.001 2.57 1.56-4.22 <0.001
 Not tested 22464.3 156 0.69  1.27 0.78-2.06 0.345 1.67 0.91-3.06 0.097
All other factors in the model were time-updated. P-values for test for heterogeneity excluded missing or not-tested values. P-values in bold 
represent significant covariates in the final model. Non-significant factors were presented in the multivariate model adjusted for significant 
predictors. IR, incidence rate; pys, person-years; HR, sub-hazard ratio; CI, confidence interval; MSM, men who have sex with men; IDU, injecting 
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Ever tested positive on HBsAg or anti-HCV.
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